Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep

• Status: Active, not recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of patients with pulmonary hypertension or with interstitial lung disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

• Precapillary pulmonary hypertension, or interstitial lung disease.

• New York Heart Association class 2-3.

• Residence at low altitude (<800m).

Exclusion Criteria:

• Unstable or exacerbated condition

• Very severe pulmonary hypertension or interstitial lung disease, New York Heart Association class 4

• requirement for oxygen therapy at low altitude residence

• hypoventilation

• more than mild or unstable cardiovascular disease

• use of drugs that affect respiratory center drive

• internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day), inability to perform 6 min walk test.

• previous intolerance to moderate altitude (<2600m).

• Exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.

• Pregnant or nursing patients